Cargando…

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) treatment includes the use of the anti-CD20 monoclonal antibody rituximab (RTX). RTX acts through Fcγ-receptors (FCGR) on effector natural killer cells and macrophages and it can be administered effectively in RA and in lymphomas. Based on the results of in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pál, Ildikó, Szamosi, Szilvia, Hodosi, Katalin, Szekanecz, Zoltan, Váróczy, László
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687551/ https://www.ncbi.nlm.nih.gov/pubmed/29177079 http://dx.doi.org/10.1136/rmdopen-2017-000485

Ejemplares similares

Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status
por: Hamar, Attila, et al.
Publicado: (2021)

Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis
por: Błyszczuk, Przemysław, et al.
Publicado: (2020)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis
por: Sweeney, Shannon R, et al.
Publicado: (2016)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
por: Bonnet, Isabelle, et al.
Publicado: (2021)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire
por: Pollastro, Sabrina, et al.
Publicado: (2019)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
por: Boers, Maarten, et al.
Publicado: (2022)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
por: Boone, Niels W, et al.
Publicado: (2019)

Activation of the Peroxisome Proliferator–Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis
por: Ma, Jian‐Da, et al.
Publicado: (2019)

Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese
por: Shirai, Yuya, et al.
Publicado: (2020)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes
por: Tu, Jiajie, et al.
Publicado: (2023)

Central Role of Semaphorin 3B in a Serum‐Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis
por: Igea, Ana, et al.
Publicado: (2022)

Attenuation of Rheumatoid Arthritis Through the Inhibition of Tumor Necrosis Factor–Induced Caspase 3/Gasdermin E–Mediated Pyroptosis
por: Zhai, Zeqing, et al.
Publicado: (2022)

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
por: Aletaha, Daniel, et al.
Publicado: (2021)

Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study
por: Nguyen, Yann, et al.
Publicado: (2022)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
por: Fleischmann, Roy, et al.
Publicado: (2022)

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
por: Dikranian, Ara H, et al.
Publicado: (2022)

Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis
por: Ahmed, Ammad, et al.
Publicado: (2016)

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients
por: Gossec, Laure, et al.
Publicado: (2019)

Identification of a 3′‐Untranslated Genetic Variant of RARB Associated With Carotid Intima‐Media Thickness in Rheumatoid Arthritis: A Genome‐Wide Association Study
por: López‐Mejías, Raquel, et al.
Publicado: (2019)

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Robinson, Michael F., et al.
Publicado: (2020)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
por: Taylor, Peter C, et al.
Publicado: (2023)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
por: Taylor, Peter C, et al.
Publicado: (2022)

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
por: Schiff, Michael, et al.
Publicado: (2015)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
por: Fleischmann, Roy M, et al.
Publicado: (2023)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_od2tmdb4klupd9oodp77drbefb